In Phase A, participants will obtain distinctive doses and schedules of oral ABBV-744 tablet to discover safe dosing regimen. More participants is going to be enrolled at the recognized monotherapy dosign routine. In Section B, members will acquire oral ruxolitinib and ABBV-744 will probably be presented as "increase-on" therapy. In https://clinicaleffectivenessofab91245.laowaiblog.com/31197357/details-fiction-and-clinical-effectiveness-of-abbv-744-in-aml-patients